Overview

NCI Definition [1]:
A methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. This agent also promotes neurotransmitter release that further stimulates the CNS. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases (PDEs). Inhibition of PDEs raises the intracellular concentration of cyclic AMP (cAMP), activates protein kinase A, and inhibits leukotriene synthesis, which leads to reduced inflammation and innate immunity.

Caffeine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating caffeine, 1 is phase 1 (1 open).

BRAF V600E and BRAF V600K are the most frequent biomarker inclusion criteria for caffeine clinical trials.

Malignant solid tumor is the most common disease being investigated in caffeine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Caffeine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating caffeine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mateína, caffeine, theine, 1,3,7-trimethylxanthine, caffeine (product), 1,3,7-trimethyl-2,6-dioxopurine, caffeine, guaranine, methyltheobromine, 1,3,7-trimethylxanthine, 3,7-dihydro-1,3,7-trimethyl-1h-purin-2,6-dion, caffeine (substance), caféine, 3,7-dihydro-1,3,7-trimethyl-1h-purine-2,6-dione, 1,3,7-trimethylpurine-2,6-dione, teina, 5036, 3,7-dihydro-1,3,7-trimethyl-1h-purine-2,6-dione, koffein, cafeína, 58-08-2, 1h-purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-, caf, theine, caffeine [chemical/ingredient], coffein, thein, 1-methyltheobromine, trimethylxanthine, methyltheobromine, 7-methyltheophylline
NCIT ID [1]:
C328
SNOMED ID [1]:
F-61117

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.